---
title: "EHR-driven Analysis of Sequential ADC Orders in Breast Cancer Using Human-Guided Agentic AI"
id: "medrxiv-18-human-guided-agentic-ai-for-end-to-end-ehr-research-sequential-antibody-drug"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-18-human-guided-agentic-ai-for-end-to-end-ehr-research-sequential-antibody-drug"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.13.26365479v1?rss=1"
published_at: "2026-10-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# EHR-driven Analysis of Sequential ADC Orders in Breast Cancer Using Human-Guided Agentic AI
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-18-human-guided-agentic-ai-for-end-to-end-ehr-research-sequential-antibody-drug
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.13.26365479v1?rss=1)
- **Published At:** 2026-10-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study combined a 4.95 million–patient **EHR** extract (June 2026) with a multi-agent AI system under Human-Guided Orchestration (HGO) to run end-to-end research workflows. - Investigators built a breast cancer cohort from 156,051 patients with relevant codes and used Muse Spark and Symbiotic Agent Teaming (SAT) to construct cohorts, run executable analyses, check data quality, retrieve literature, and draft reports. - The clinical use case examined sequential antibody–drug conjugate (ADC) orders: **sacituzumab govitecan** (SG) and **trastuzumab deruxtecan** (T-DXd). - The primary clinical measure was the second-drug record span, defined as the interval from first order to last order of the second agent; analyses were descriptive and unadjusted. - The workflow identified 106 patients with sequential ADC orders: 73 had T-DXd ordered first, 33 had SG ordered first. - Median second-drug spans: 63 days (IQR 29–116) for SG after T-DXd; 49 days (IQR 21–126) for T-DXd after SG; median difference −14 days (95% bootstrap CI −41 to 21; distributional P = 0.42). - Orders were not validated as administrations, and the dataset did not include prospective clinical outcomes or progression confirmation. - Reported outputs included cohort definitions, aggregated analyses, figures, an evidence context, and a preliminary manuscript draft. - Ethical oversight: retrospective deidentified data, Bluebonnet IRB determined the study IRB exempt with waivers of consent under 45 CFR 46.104(d)(4). - Patient-level records are licensed third-party data and are not redistributed; accompanying files include aggregate results, operational definitions, and partial code but do not permit independent cohort reproduction.
## Clinical Analysis & Structured Key Points
Human-Guided Agentic AI for End-to-End EHR Research: Sequential Antibody-Drug Conjugate Pathways in Breast Cancer | medRxiv Skip to main content Human-Guided Agentic AI for End-to-End EHR Research: Sequential Antibody-Drug Conjugate Pathways in Breast Cancer View ORCID Profile Arturo Loaiza-Bonilla , View ORCID Profile Christos Colovos , View ORCID Profile Daniel Kim , View ORCID Profile James M. Grichnik , View ORCID Profile Kritika Singh , View ORCID Profile Paolo Tarantino doi: https://doi.org/10.64898/2026.10.13.26365479 Arturo Loaiza-Bonilla 1 Meta Platforms, Inc., Menlo Park, California, USA; St. Luke's University Health Network, Bethlehem, Pennsylvania, USA; Massive Bio, Inc., Boca Raton, Florida, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Arturo Loaiza-Bonilla For correspondence: arturolbmd{at}gmail.com Christos Colovos 2 Meta Platforms, Inc., Menlo Park, California, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Christos Colovos Daniel Kim 2 Meta Platforms, Inc., Menlo Park, California, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Daniel Kim James M. Grichnik 3 Meta Platforms, Inc., Menlo Park, California, USA; Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, Florida, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for James M. Grichnik Kritika Singh 4 Meta Platforms, Inc., Menlo Park, California, USA; Stanford University School of Medicine, Stanford, California, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kritika Singh Paolo Tarantino 5 Dana-Farber Cancer Institute, Boston, Massachusetts, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Paolo Tarantino Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract PURPOSE: To demonstrate an end-to-end research workflow combining a large electronic health record (EHR) resource and a multi-agent artificial intelligence (AI) system governed by Human-Guided Orchestration (HGO), using sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) orders in breast cancer as the clinical use case. METHODS: A June 2026 EHR release contained 4.95 million patients, including 156,051 with breast cancer codes. Muse Spark supported cohort construction, executable statistical analysis, data-quality checks, literature retrieval, and reporting executed through Symbiotic Agent Teaming (SAT) under investigator direction. The main clinical measure was the second-drug record span, from first to last order. Analyses were descriptive and unadjusted; orders did not confirm administration or progression. RESULTS: The workflow identified 106 patients: 73 had T-DXd ordered first and 33 had SG ordered first. Median second-drug spans were 63 days (interquartile range [IQR], 29-116) for SG after T-DXd and 49 days (IQR, 21-126) for T-DXd after SG; the median difference was -14 days (95% bootstrap CI, -41 to 21; distributional P = 0.42). Reported outputs additionally included cohort definitions, aggregate analyses, evidence context, figures, and a preliminary draft manuscript. CONCLUSION: This study provides a concrete model for integrating large EHR resources, agentic AI, and human expertise across the research cycle. The ADC use case illustrates how computational execution and Expert-in-the-Loop (EITL) adjudication can produce interpretable research outputs and refine their scientific meaning, providing a foundation for extending and evaluating this approach across clinical questions. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics approval and consent to participate: This study was conducted in accordance with guidelines of the Declaration of Helsinki, Belmont report, and U.S. Common rule. In keeping with 45 CFR 46.104(d)(4), this study was performed utilizing retrospective, deidentified clinical data, and is considered IRB exempt with waivers of patient informed consent. Waiver of patient consent and exempt status was determined by Bluebonnet IRB. Consent for publication: Not applicable. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Patient-level records are licensed third-party data and are not redistributed with this manuscript. The accompanying files contain reported aggregate results, operational definitions, and code for a limited audit of publicly reported counts and figure generation. That code does not reproduce cohort selection, patient-level statistics, or clinical validation. No public repository DOI or independent reproduction is claimed. Funder Information Declared Meta (United States), https://ror.org/01zbnvs85 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 14, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Human-Guided Agentic AI for End-to-End EHR Research: Sequential Antibody-Drug Conjugate Pathways in Breast Cancer Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Human-Guided Agentic AI for End-to-End EHR Research: Sequential Antibody-Drug Conjugate Pathways in Breast Cancer Arturo Loaiza-Bonilla , Christos Colovos , Daniel Kim , James M. Grichnik , Kritika Singh , Paolo Tarantino medRxiv 2026.10.13.26365479; doi: https://doi.org/10.64898/2026.10.13.26365479 Share This Article: Copy Citation Tools Human-Guided Agentic AI for End-to-End EHR Research: Sequential Antibody-Drug Conjugate Pathways in Breast Cancer Arturo Loaiza-Bonilla , Christos Colovos , Daniel Kim , James M. Grichnik , Kritika Singh , Paolo Tarantino medRxiv 2026.10.13.26365479; doi: https://doi.org/10.64898/2026.10.13.26365479 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (628) Allergy and Immunology (914) Anesthesia (343) Cardiovascular Medicine (4923) Dentistry and Oral Medicine (488) Dermatology (421) Emergency Medicine (667) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1655) Epidemiology (16115) Forensic Medicine (35) Gastroenterology (1227) Genetic and Genomic Medicine (7167) Geriatric Medicine (740) Health Economics (1079) Health Informatics (5179) Health Policy (1452) Health Systems and Quality Improvement (1807) Hematology (595) HIV/AIDS (1362) Infectious Diseases (except HIV/AIDS) (16395) Intensive Care and Critical Care Medicine (1187) Medical Education (684) Medical Ethics (156) Nephrology (733) Neurology (7434) Nursing (372) Nutrition (1110) Obstetrics and Gynecology (1274) Occupational and Environmental Health (1020) Oncology (3686) Ophthalmology (1077) Orthopedics (400) Otolaryngology (461) Pain Medicine (488) Palliative Medicine (142) Pathology (714) Pediatrics (1837) Pharmacology and Therapeutics (744) Primary Care Research (780) Psychiatry and Clinical Psychology (6030) Public and Global Health (9882) Radiology and Imaging (2479) Rehabilitation Medicine and Physical Therapy (1494) Respiratory Medicine (1258) Rheumatology (654) Sexual and Reproductive Health (791) Sports Medicine (591) Surgery (792) Toxicology (109) Transplantation (313) Urology (299)
## Related Clinical Research

- [Right-sizing therapy for HER2-positive breast cancer across early and advanced stages](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-1-right-sizing-treatment-for-her2-positive-breast-cancer-evolving-algorithms.md)
- [Advances in Systemic Treatment of Breast Cancer: Targeted Therapies, ADCs, and Immunotherapy](https://medichelpline.com/clinical-feed/pubmed-42842904.md) (DOI: 10.1056/NEJMra2500695)
- [Immunological effects of antibody–drug conjugates: mechanisms, combos and next‑generation designs](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-exploring-the-immunological-effects-of-antibody-drug-conjugates.md)
- [T-DXd vs Other HER2-targeted Therapies in Later-Line HER2+ Metastatic Breast Cancer: Bayesian NMA](https://medichelpline.com/clinical-feed/pubmed-42809558.md) (DOI: 10.1371/journal.pone.0358540)
- [Trastuzumab + nivolumab with gemcitabine–cisplatin as first-line therapy for HER2-positive unresec](https://medichelpline.com/clinical-feed/nature-3-trastuzumab-plus-nivolumab-with-gemcitabine-and-cisplatin-as-first-line-therapy.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.